Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing covers the month of March 2026, specifically detailing a share repurchase executed on March 16, 2026. The transaction was conducted by BNP Paribas SA acting as the broker under a non-discretionary agreement announced on February 17, 2026.
Key Financial Metrics
The filing details a specific share buyback transaction rather than comprehensive financial statements. Key metrics for the transaction on March 16, 2026, include:
- Shares Purchased: 628,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 2,026.00 GBp; highest price paid was 2,052.00 GBp.
- Average Price: Volume-weighted average price paid was 2,035.82 GBp.
- Program Progress: Since the program start on February 17, 2026, the Company has purchased 10,553,409 ordinary shares.
- Treasury Holdings: Following this purchase, GSK holds 250,444,503 ordinary shares in treasury.
- Shares in Issue: 4,065,726,262 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 6.16% of the total voting rights.
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury stock due to the buyback program. The filing does not provide comparative financial data (revenue, profit, or cash flow) for the period, nor does it detail changes in debt or liquidity positions beyond the capital allocation for the share repurchase.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These risks are referenced as being described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2025. The filing confirms the purchase was part of an existing buyback program.
Investor Verification Checklist
- Verify the total remaining authorization under the buyback program announced on February 17, 2026.
- Confirm the impact of the 6.16% treasury holding on earnings per share (EPS) calculations.
- Review the "Risk Factors" in the 2025 Form 20-F for context on the forward-looking statement disclaimer.
- Monitor subsequent filings for updates on the total volume of shares repurchased under the current program.